Publications by authors named "Deborah L Keefe"

Claim this Profile
E
Efficacy, safety, and tolerability of aliskiren monotherapy administered with a light meal in elderly hypertensive patients: a randomized, double-blind, placebo-controlled, dose-response evaluation study.
Giuseppe Villa, Stephanie Le Breton, Ghionul Ibram, Deborah L Keefe

J Clin Pharmacol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antihypertensive treatment in patients with class 3 obesity.
Jens Jordan, Sam W Boye, Stephanie Le Breton, Deborah L Keefe, Stefan Engeli

Ther Adv Endocrinol Metab· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
Domenic Sica, Alan H Gradman, Ole Lederballe, Rainer E Kolloch, Jack Zhang, Deborah L Keefe

Clin Drug Investig· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.
Raymond R Townsend, Alan D Forker, Vaishali Bhosekar, Anthony Yadao, Deborah L Keefe

J Clin Hypertens (Greenwich)· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: a pooled analysis of clinical experience of 12,942 patients.
William B White, Robert Bresalier, Allen P Kaplan, Biff F Palmer, Robert H Riddell, Deborah L Keefe

J Clin Hypertens (Greenwich)· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of body weight and gender on the pharmacokinetics, pharmacodynamics, and antihypertensive efficacy of aliskiren.
Venkateswar Jarugula, Ching-Ming Yeh, Dan Howard, Christopher Bush, Deborah L Keefe

J Clin Pharmacol· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.
Karl Andersen, Myron H Weinberger, Brent Egan, Christian M Constance, Melanie Wright, Deborah L Keefe

Cardiovasc Ther· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension.
William B White, Robert Bresalier, Allen P Kaplan, Biff F Palmer, Robert H Riddell, Deborah L Keefe

J Clin Hypertens (Greenwich)· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the dose--response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension.
Juan G Puig, Heribert Schunkert, Addison A Taylor, Sam Boye, James Jin, Deborah L Keefe

Clin Ther· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.
Karl Andersen, Myron H Weinberger, Christian M Constance, Mohammed A Ali, James Jin, Deborah L Keefe

J Renin Angiotensin Aldosterone Syst· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial.
Roland E Schmieder, Thomas Philipp, Javier Guerediaga, Manuel Gorostidi, Christopher Bush, Deborah L Keefe

J Hypertens· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety, tolerability, and antihypertensive efficacy of aliskiren, an oral direct renin inhibitor, in Japanese patients with hypertension.
Toshio Kushiro, Hiroshige Itakura, Yoshihisa Abo, Hiromi Gotou, Shinji Terao, Deborah L Keefe

Hypertens Res· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension.
Rainer Dietz, Ralf Dechend, Chuek-Man Yu, Manesh Bheda, Jessica Ford, Deborah L Keefe

J Renin Angiotensin Aldosterone Syst· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
John J V McMurray, Bertram Pitt, Roberto Latini, Aldo P Maggioni, Scott D Solomon, Deborah L Keefe

Circ Heart Fail· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
Karl Andersen, Myron H Weinberger, Brent Egan, Christian M Constance, Mohammed A Ali, Deborah L Keefe

J Hypertens· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.
Waymon Drummond, Mark A Munger, Mohammed Rafique Essop, Mojdeh Maboudian, Mahmudul Khan, Deborah L Keefe

J Clin Hypertens (Greenwich)· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Jens Jordan, Stefan Engeli, Sam W Boye, Stephanie Le Breton, Deborah L Keefe

Hypertension· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension.
Byung-Hee Oh, Jerry Mitchell, James R Herron, Jenny Chung, Mahmudul Khan, Deborah L Keefe

J Am Coll Cardiol· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension.
Toshio Kushiro, Hiroshige Itakura, Yoshihisa Abo, Hiromi Gotou, Shinji Terao, Deborah L Keefe

Hypertens Res· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QTc interval prolongation associated with intravenous methadone.
Craig A Kornick, Michael J Kilborn, Juan Santiago-Palma, Glenn Schulman, Howard T Thaler, Deborah L Keefe

Pain· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab-associated cardiotoxicity.
Deborah L Keefe

Cancer· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?
Deborah L Keefe

Oncologist· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis